Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
GXAI
Gaxos.ai
Sponsored
content by Gaxos.ai
JO
Jolt_Communications
Community Contributor
Gaxos.ai: Early-Stage AI Innovator in Gaming & Health
Key Takeaways Dual AI focus – Gaxos.ai builds AI-powered tools for game developers (via Unity integrations) and AI-driven health services under its RNK Health brand. First signs of commercial traction – After years of development, the company reported ~$194k in H1 2025 revenue, mainly from wellness pilot programs.
View narrative
US$2.21
FV
5.9% undervalued
intrinsic discount
119.00%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
1
users have commented on this narrative
30
users have followed this narrative
Updated
narrative
Microsoft
PI
PicaCoder
Community Contributor
After the AI Party: A Sobering Look at Microsoft's Future
The world has been captivated by the artificial intelligence boom, and no company has ridden the wave of investor enthusiasm quite like Microsoft. Buoyed by its strategic partnership with OpenAI and the integration of AI across its product ecosystem, the company's valuation has soared to unprecedented heights.
View narrative
US$500.00
FV
1.4% overvalued
intrinsic discount
6.75%
Revenue growth p.a.
Set Fair Value
21
users have liked this narrative
12
users have commented on this narrative
27
users have followed this narrative
12 days ago
author updated this narrative
Amazon.com
ZW
Zwfis
Community Contributor
Amazon's Future Rises as Stock Price Falls: A Long-Term Investment Vision
Amazon is a stock I am very interested in right now especially with the recent price drops that it has been experiencing since its 2Q25 results. A summary of Amazon as stated by Fiscal.ai: "Amazon.com, Inc.
View narrative
US$234.75
FV
2.5% undervalued
intrinsic discount
13.60%
Revenue growth p.a.
Set Fair Value
20
users have liked this narrative
7
users have commented on this narrative
25
users have followed this narrative
New
narrative
Verve Group
TI
TibiT
Community Contributor
Verve Group: A Tale of Three Futures
Verve Group stands at a critical juncture. After a history of explosive growth, the company has been hit by significant operational headwinds, primarily the difficult and costly migration to a unified technology platform and unfavorable currency exchange rates.
View narrative
€4.02
FV
44.5% undervalued
intrinsic discount
8.50%
Revenue growth p.a.
Set Fair Value
3
users have liked this narrative
0
users have commented on this narrative
15
users have followed this narrative
New
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
Regeneron Pharmaceuticals
AN
AnalystHighTarget
Consensus Narrative from 23 Analysts
Dupixent And EYLEA Will Seize Expanding Global Markets
Key Takeaways Regeneron's best-in-class therapies, strong product adoption, and innovative pipeline position it for rapid market share gains and expanded, diversified long-term growth. Strategic investments in manufacturing and advanced biologics platforms enable operational efficiency, robust supply, and capitalize on rising global demand for precision medicines.
View narrative
US$890.00
FV
33.8% undervalued
intrinsic discount
7.68%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
0
users have commented on this narrative
3
users have followed this narrative
4 days ago
author updated this narrative
Bristol-Myers Squibb
AN
AnalystHighTarget
Consensus Narrative from 21 Analysts
Pipeline Launches And Global Healthcare Trends Will Unlock Growth
Key Takeaways Robust portfolio performance and pipeline innovation, especially in immuno-oncology, are fueling faster-than-expected revenue growth and international market expansion. Strong cost discipline, operational efficiencies, and AI-driven R&D enhancements are creating substantial upside for margins and long-term earnings growth.
View narrative
US$68.00
FV
29.5% undervalued
intrinsic discount
-3.04%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
2
users have followed this narrative
4 days ago
author updated this narrative
Vertex Pharmaceuticals
AN
AnalystHighTarget
Consensus Narrative from 25 Analysts
Gene Editing And Precision Medicines Will Serve Aging Populations
Key Takeaways Superior new treatments and breakthrough therapies are set to accelerate growth, replace older products, and drive market leadership in chronic and genetic diseases. Strong financials enable aggressive R&D, pipeline expansion, and strategic deals, supporting sustained margin growth and earnings outperformance.
View narrative
US$618.10
FV
36.1% undervalued
intrinsic discount
14.03%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
4 days ago
author updated this narrative
NextEra Energy
AN
AnalystHighTarget
Consensus Narrative from 18 Analysts
Accelerated Decarbonization And Electrification Will Reshape Energy Markets
Key Takeaways NextEra's scale, advanced storage, and unique asset repositioning could lead to outperformance in revenue, margins, and market share as energy demand accelerates. Aggressive investments in nuclear, grid digitalization, and all-source solutions position NextEra for sustained growth and premium pricing in a rapidly electrifying economy.
View narrative
US$103.00
FV
25.9% undervalued
intrinsic discount
15.20%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
8
users have followed this narrative
4 days ago
author updated this narrative
United Parcel Service
AN
AnalystHighTarget
Consensus Narrative from 30 Analysts
Omni-channel Retail And Automation Will Unlock Global Efficiency
Key Takeaways Rapid automation and cost-cutting efforts are improving margins, product mix, and cash flow, with potential to exceed market expectations for sustainable profitability. Strategic expansion in healthcare logistics and global trade routes, combined with digital investments, is positioning the company for robust, diversified long-term growth.
View narrative
US$132.27
FV
32.9% undervalued
intrinsic discount
2.26%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
7
users have followed this narrative
4 days ago
author updated this narrative
Lifeway Foods
AN
AnalystConsensusTarget
Consensus Narrative from 1 Analyst
Target Retail Expansion And Consumer Health Focus Will Create Momentum
Key Takeaways Growing consumer demand for gut health and functional foods, combined with product innovation, is strengthening competitive advantage and supporting higher margins. Expanded national retail distribution and operational efficiency improvements are driving greater market penetration, improved cost structure, and enhanced earnings potential.
View narrative
US$33.00
FV
3.8% undervalued
intrinsic discount
14.87%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
0
users have commented on this narrative
11
users have followed this narrative
4 days ago
author updated this narrative
Chicago Atlantic Real Estate Finance
AN
AnalystConsensusTarget
Consensus Narrative from 4 Analysts
Cannabis Lending Expansion Will Unlock Opportunities Amid Credit Risks
Key Takeaways Continued regulatory barriers for cannabis operators enable pricing power and high yields, supporting strong net interest margins and profitability. Strategic positioning and portfolio diversification allow for steady growth, scalable earnings, and resilience against credit losses in the evolving cannabis finance market.
View narrative
US$17.63
FV
18.2% undervalued
intrinsic discount
2.21%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
7
users have followed this narrative
4 days ago
author updated this narrative
Limoneira
AN
AnalystConsensusTarget
Consensus Narrative from 2 Analysts
Transforming Land And Expanding Avocado Production Will Unlock Future Value
Key Takeaways Strategic land use and water resource monetization aim to enhance net margins through efficient asset utilization. Diversification into avocados and foodservice stabilizes revenue streams while reducing reliance on volatile lemon markets.
View narrative
US$27.00
FV
38.8% undervalued
intrinsic discount
-11.56%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
2
users have followed this narrative
4 days ago
author updated this narrative
Solaris Energy Infrastructure
AN
AnalystConsensusTarget
Consensus Narrative from 9 Analysts
Grid Resiliency And Electrification Will Drive Modular Power Generation
Key Takeaways Rising demand for resilient power infrastructure and regulatory support are fueling Solaris's growth and securing longer-term contracts, increasing revenue certainty and earnings stability. The shift to higher-margin owned assets and continued technology investment are set to boost profitability, strengthen customer relationships, and expand Solaris's market reach.
View narrative
US$45.22
FV
36.6% undervalued
intrinsic discount
28.93%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
14
users have followed this narrative
4 days ago
author updated this narrative
Value any company in seconds
Popular companies